Company news
Cingulate Inc. (NASDAQ:CING) news
Cingulate Inc. news releases on 6ix. Latest, Sep 5, 2023: Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial…
Press releases — page 2
Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023
September 4, 2023
Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
August 13, 2023
Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
July 10, 2023
Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August
June 28, 2023
Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
June 7, 2023
Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
May 9, 2023
Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO
May 2, 2023
Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD
April 3, 2023
Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301
March 12, 2023
Cingulate Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update
March 9, 2023
Cingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset CTx-1301 for ADHD
February 22, 2023
Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD
January 3, 2023
Cingulate Inc. Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update
November 13, 2022
Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD
October 31, 2022
Cingulate Announces Agreement with Societal CDMO and Provides Clinical Update
October 23, 2022
Cingulate Presents Data for Its Triple-Release Buspirone Product Candidate: CTx-2103
September 18, 2022
Cingulate Inc. Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update
August 10, 2022
Cingulate Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders
June 22, 2022
Cingulate Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety Disorders
May 23, 2022
Cingulate Inc. Reports First Quarter 2022 Results and Provides Clinical and Business Update
May 11, 2022
Cingulate Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Clinical and Business Update
March 9, 2022
Cingulate Provides 2022 Clinical Plan for CTx-1301, an Investigational Medication for Attention Deficit/Hyperactivity Disorder (ADHD)
February 7, 2022
Cingulate Appoints Curt Medeiros and Gregg Givens to Board of Directors
January 24, 2022
Cingulate Inc. Announces Closing of Initial Public Offering
December 9, 2021
Cingulate Inc. Announces Pricing of $25.0 Million Initial Public Offering
December 6, 2021